{"gene":"SOS1","run_date":"2026-06-10T07:46:38","timeline":{"discoveries":[{"year":2006,"finding":"Missense mutations in SOS1 that cluster at residues maintaining autoinhibition cause Noonan syndrome by acting as hypermorphs: ectopic expression of two Noonan syndrome-associated SOS1 mutants enhances RAS and ERK activation, identifying SOS1 as a RAS guanine nucleotide exchange factor whose gain-of-function causes disease.","method":"Ectopic expression of mutant SOS1 constructs in cell lines with RAS-GTP and ERK activation readouts; genetic mapping in human patients","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated independently in two simultaneous papers (PMID:17143285 and PMID:17143282) using ectopic expression and biochemical readouts, with structural/domain inference supported by both studies","pmids":["17143285","17143282"],"is_preprint":false},{"year":1996,"finding":"MAP kinase phosphorylates human SOS1 on five C-terminal serine residues (S1137, S1167, S1178, S1193, S1197) clustered within the proline-rich SH3-binding domain; replacing four of these sites with alanine increases Grb2 binding affinity, indicating that MAP kinase-mediated phosphorylation negatively regulates Grb2–SOS1 interaction and thereby modulates RAS activation.","method":"Site-directed mutagenesis combined with in vitro phosphorylation assays and Grb2 binding affinity measurements","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis of specific phosphorylation sites with direct binding affinity measurements, multiple orthogonal methods in one study","pmids":["8816480"],"is_preprint":false},{"year":1994,"finding":"After M-CSF stimulation, SOS1 forms complexes with Grb2 and the Fms receptor (M-CSF receptor) in myeloid cells; SOS1 also co-immunoprecipitates with Shc, and neither Grb2 nor SOS1 in these complexes contains phosphotyrosine, indicating SOS1 is recruited to the activated receptor via Grb2 adaptor interactions.","method":"Co-immunoprecipitation and SH2/SH3 domain-binding assays in M-CSF-stimulated myeloid progenitor cells","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP with domain-binding confirmation, single lab but multiple orthogonal binding assays","pmids":["7520523"],"is_preprint":false},{"year":2004,"finding":"The non-receptor tyrosine kinase Abl phosphorylates SOS1 on tyrosine after RTK activation; Abl-induced tyrosine phosphorylation of SOS1 is sufficient to elicit its RAC-GEF activity in vitro, and SOS1 interacts with Abl in vivo, defining an RTK–Abl–SOS1–Rac pathway for actin remodeling.","method":"In vitro RAC-GEF activity assay, co-immunoprecipitation, pharmacological and genetic Abl inhibition","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro GEF reconstitution assay plus co-IP plus genetic/pharmacological interference, multiple orthogonal methods in one study","pmids":["15039778"],"is_preprint":false},{"year":2000,"finding":"Targeted disruption of mouse sos1 causes mid-gestational embryonic lethality due to impaired placental trophoblast development with very low ERK activity; sos1-null cells show reduced transformation by v-Src or overexpressed EGFR and reduced long-term ERK activation, whereas Sos2 compensates only for short-term signaling, demonstrating that SOS1 is specifically required for sustained RAS–ERK signaling downstream of EGFR.","method":"Homologous recombination knockout mice; transformation assays; ERK activation time-course in sos1−/− cell lines","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with multiple defined cellular phenotypes and mechanistic comparison with Sos2, replicated across cell-based and in vivo readouts","pmids":["10675333"],"is_preprint":false},{"year":1997,"finding":"Heterozygous Sos1 mutation dominantly enhances the phenotype of a weak EGFR allele (wa-2) in mice, producing eye defects resembling EGFR or TGF-α nulls; homozygous Sos1-null embryos die mid-gestation with cardiovascular/yolk sac defects and reduced EGF-stimulated MAP kinase activation in fibroblasts, establishing a genetic requirement for SOS1 in EGFR signaling in vivo.","method":"Genetic epistasis in mice (Sos1/EGFR double mutant); ERK activation assay in null fibroblasts","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo epistasis combined with biochemical ERK readout in knockout cells, two independent genetic approaches","pmids":["9030684"],"is_preprint":false},{"year":2002,"finding":"A frameshift insertion mutation in codon 1083 of SOS1 (insertion of cytosine between nucleotides 126,142 and 126,143) is responsible for hereditary gingival fibromatosis type 1 (HGF1); the mutation abolishes four C-terminal proline-rich SH3-binding domains, creating a truncated SOS1 chimera that retains the catalytic domain and, based on analogous transgenic mouse constructs, produces skin/tissue hypertrophy.","method":"Positional cloning, sequencing of SOS1 in affected family members, segregation analysis over four generations","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct mutation identification with segregation analysis; functional inference from analogous transgenic mouse data cited but not performed in this study","pmids":["11868160"],"is_preprint":false},{"year":2007,"finding":"Truncated SOS1 carrying the hereditary gingival fibromatosis mutation localizes to the plasma membrane without growth factor stimulation, producing sustained RAS/MAPK/ERK activation, phosphorylation of Rb, and upregulation of cyclins C, D, E and E2F/DP transcription factors, driving cell cycle G1-to-S progression and increased fibroblast proliferation.","method":"Ectopic expression of wild-type and mutant SOS1 constructs; siRNA knockdown; ERK phosphorylation and cell-cycle marker immunoblotting","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ectopic expression plus siRNA with multiple biochemical and cell-cycle readouts, single lab","pmids":["17510059"],"is_preprint":false},{"year":2010,"finding":"SOS1 forms a tri-complex with EPS8 and ABI1 in ovarian cancer cells; the integrity of this SOS1/EPS8/ABI1 complex is required for LPA-induced Rac activation and subsequent cell migration and peritoneal metastatic colonization; re-expression of the missing complex member in non-metastatic cells confers metastatic capability.","method":"Co-immunoprecipitation, knockdown, ectopic re-expression, Rac-GTP assay, in vivo peritoneal colonization assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus functional rescue experiments plus in vivo colonization assay, multiple orthogonal methods","pmids":["21118970"],"is_preprint":false},{"year":2012,"finding":"RSK phosphorylates SOS1 on Ser1134 and Ser1161 in cultured cells; these phosphorylations create 14-3-3 docking sites, and mutating these residues disrupts 14-3-3 binding and modestly increases and extends MAP kinase activation, identifying RSK-mediated SOS1 phosphorylation as a negative feedback mechanism restraining MAPK signaling.","method":"Quantitative mass spectrometry, pharmacological RSK inhibition, mutagenesis of phosphorylation sites, 14-3-3 binding assays, ERK activation time-course","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — MS-identified phosphosites, mutagenesis confirming 14-3-3 binding, functional ERK readout; multiple orthogonal methods in one study","pmids":["22827337"],"is_preprint":false},{"year":2011,"finding":"Conditional deletion of Sos1 in thymocytes reveals that SOS1 is required for pre-TCR-stimulated (DN-to-DP transition) but not TCR-stimulated developmental signals; Sos1-deficient thymocytes show reduced pre-TCR-induced proliferation, differentiation, and ERK phosphorylation, while TCR-dependent positive and negative selection remain intact.","method":"Conditional (floxed allele) knockout mice; thymocyte subset analysis; ERK phosphorylation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean conditional KO with stage-specific phenotypic readouts and biochemical ERK measurement, multiple in vivo and ex vivo approaches","pmids":["21746917"],"is_preprint":false},{"year":2013,"finding":"SOS1 and Grb2 cooperatively control embryonic stem cell fate toward the primitive endoderm lineage via FGF signaling; this requires collective binding of multiple SOS1/Grb2 domains (SH3, SH2, REM, PH domains) to both protein and phospholipid ligands, providing a cooperative threshold mechanism for lineage commitment.","method":"Domain mutagenesis, protein-protein interaction assays, ES cell differentiation assays, genetic rescue experiments","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic domain mutagenesis combined with cell-fate readouts and biochemical interaction studies, multiple orthogonal methods","pmids":["23452850"],"is_preprint":false},{"year":1999,"finding":"SOS1 acts as a guanine nucleotide exchange factor for M-Ras (R-Ras3) in addition to classical RAS proteins; M-Ras GTP/GDP cycling is sensitive to SOS1 and GRF1 (GEFs) and to p120 RasGAP, demonstrating that SOS1 GEF activity extends to the M-Ras subfamily.","method":"GDP/GTP exchange assay, yeast two-hybrid, co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro GEF assay demonstrating SOS1 acts on M-Ras, single lab but direct biochemical measurement","pmids":["10446149"],"is_preprint":false},{"year":2000,"finding":"SOS1 directly binds the SH3 domain of PLC-γ1 through its C-terminal proline-rich domain; this interaction is detected both in vitro (GST pulldown) and in cells (co-immunoprecipitation); overexpression of PLC-γ1 or its SH2-SH2-SH3 domain elevates p21Ras and ERK activity, and a PLC-γ1 mutant lacking the SH3 domain cannot activate RAS, linking PLC-γ1 SH3 binding to SOS1-mediated RAS activation.","method":"GST pulldown, co-immunoprecipitation, transient expression with RAS-GTP and ERK activity assays","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — GST pulldown plus co-IP plus functional GEF readout, single lab, multiple methods","pmids":["10913276"],"is_preprint":false},{"year":2014,"finding":"SOS1 silencing inhibits EGF-induced NFκB activation in cancer cells, and SOS1 overexpression increases NFκB activation; importantly, the guanine nucleotide exchange activity of SOS1 is NOT required for NFκB activation, indicating SOS1 has a GEF-independent scaffolding role in the EGFR–NFκB pathway.","method":"RNAi knockdown, SOS1 overexpression, NFκB reporter assays, GEF-dead mutant analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown plus OE with GEF-dead mutant control, single lab, multiple cell line confirmation","pmids":["25071181"],"is_preprint":false},{"year":2014,"finding":"SOS1 is required for sustained but not transient TCR-mediated ERK activation in primary human T cells; RasGRP1 mediates transient ERK activation while both SOS1 and RasGRP1 are required for sustained ERK signaling and T-cell activation.","method":"RNAi-mediated knockdown of SOS1, SOS2, and RasGRP1 in primary human T cells; ERK phosphorylation kinetics under transient vs. sustained TCR stimulation","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — selective siRNA knockdown with defined temporal ERK readout, single lab, clean experimental design","pmids":["24497027"],"is_preprint":false},{"year":2014,"finding":"SOS1, acting through the RAS/MEK/ERK pathway, is essential for tight junction formation in human bronchial epithelial cells; global microarray analysis identifies EMP1 as a major SOS1-dependent transcriptional target, and EMP1 itself is required for tight junction assembly.","method":"RNAi screen for GEFs, SOS1-specific knockdown, microarray analysis, tight junction assembly assay","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi screen followed by targeted knockdown with pathway and transcriptional readouts, single lab but multiple orthogonal approaches","pmids":["25394671"],"is_preprint":false},{"year":2015,"finding":"SOS1 localizes to macrophage podosomes; its silencing results in podosome disassembly, reduced Rac-GTP loading, and impaired matrix degradation, 3D migration, transmigration through endothelial monolayers, and invasion into tumor spheroids. Abl and Src kinases (Hck, Fgr) phosphorylate SOS1 to mediate Abl/SOS1 interaction and podosome-associated Rac GEF activity.","method":"siRNA knockdown, co-immunoprecipitation, Rac-GTP pull-down assay, Matrigel invasion assay, live cell imaging of podosome markers","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — targeted siRNA knockdown with multiple functional readouts and biochemical Rac-GTP assay, single lab","pmids":["26447228"],"is_preprint":false},{"year":2016,"finding":"Sos1-specific knockout in primary mouse embryonic fibroblasts causes impaired proliferation and migration, altered cytoskeletal organization, accumulation of autophagosomes containing degraded mitochondria (mitophagy), and elevated intracellular reactive oxygen species and mitochondrial superoxide; antioxidant treatment restores proliferation and morphology, establishing a mechanistic link between SOS1 and control of mitochondrial oxidative stress.","method":"Conditional 4-OHT-inducible Sos1-null MEFs; electron microscopy; mitophagy/autophagosome markers; ROS and mitochondrial superoxide fluorescent labeling; antioxidant rescue","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean conditional KO with multiple orthogonal readouts (EM, ROS assays, antioxidant rescue), mechanistic link established within single study","pmids":["27157612"],"is_preprint":false},{"year":2017,"finding":"SOS1 is tyrosine phosphorylated on Y1196 by ABL; this phosphorylation controls SOS1 inter-molecular interactions, is required for RAC nucleotide exchange in vitro, and is needed for PDGF-induced RAC activation and actin remodeling/cell migration. In BCR-ABL leukemic cells, Y1196 phosphorylation by BCR-ABL drives SOS1-dependent RAC activation, cell proliferation, and transformation; genetic Sos1 removal delays BCR-ABL leukemogenesis in vivo.","method":"In vitro RAC-GEF assay with phospho-Y1196 SOS1; co-immunoprecipitation; mutagenesis; Sos1 conditional knockout in bone marrow; xenograft leukemogenesis model","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro GEF reconstitution with phosphomimetic mutants, in vivo leukemogenesis model, multiple orthogonal methods","pmids":["28819285"],"is_preprint":false},{"year":2015,"finding":"Two distinct RAS exchange factors, RasGRP1 and SOS1, act downstream of EGFR but in functional opposition: SOS1 drives proliferative EGFR-Ras signals, while RasGRP1 creates a negative feedback loop that limits EGFR-SOS1-RAS signals; genetic Rasgrp1 depletion in KRas-mutant or Apc-mutant mice exacerbates Ras-ERK signaling, confirming the epistatic relationship.","method":"Genetic mouse models (Rasgrp1 depletion combined with KRas or Apc mutations), ERK signaling assays, cell proliferation measurements","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in multiple mouse models combined with biochemical ERK readouts, independently confirmed in two genetic backgrounds","pmids":["26005835"],"is_preprint":false},{"year":2001,"finding":"The vacuolar H+-ATPase E subunit (V-ATPase E) binds the Dbl-homology (DH) domain of SOS1, co-immunoprecipitates with SOS1 physiologically, and co-localizes with SOS1 and Rac1 in early endosomes; overexpression of V-ATPase E enhances SOS1-mediated RAC1 guanine nucleotide exchange activity and downstream JNK kinase activity, implicating V-ATPase E as a positive regulator of the SOS1-Rac1 pathway at endosomes.","method":"GST-affinity chromatography protein purification, peptide sequencing, yeast two-hybrid, co-immunoprecipitation, subcellular fractionation, in vitro Rac1-GEF assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple binding methods plus in vitro GEF activity readout, single lab","pmids":["11560919"],"is_preprint":false},{"year":2019,"finding":"SOS1 mutations found in lung adenocarcinoma function as oncogenic gain-of-function: ectopic expression induces anchorage-independent growth and tumor formation in vivo; these effects require both the RAS-GEF and putative RAC-GEF activities of SOS1, and mutant SOS1-expressing cancer cells are sensitive to MEK inhibition.","method":"Ectopic expression of lung adenocarcinoma-derived SOS1 mutants; anchorage-independent growth assay; mouse xenograft tumor formation; domain mutagenesis; transcriptional profiling; MEK inhibitor sensitivity assay","journal":"Molecular cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ectopic expression plus mutagenesis plus in vivo xenograft, multiple orthogonal methods demonstrating gain-of-function mechanism","pmids":["30635434"],"is_preprint":false},{"year":2020,"finding":"Crystal structures of KRAS-SOS1, SOS1, and SOS2 were solved; BI-3406 binds to the catalytic domain of SOS1, preventing SOS1–KRAS interaction; this blocks GTP loading of RAS, reduces RAS-GTP levels, limits cancer cell proliferation, and attenuates feedback reactivation of MEK inhibitors, validating the SOS1 catalytic domain as a druggable interface.","method":"Crystal structure determination, biochemical SOS1–KRAS interaction assay, cellular RAS-GTP loading assay, proliferation assays, in vivo xenograft experiments","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures combined with biochemical and cellular mechanistic validation, multiple orthogonal methods","pmids":["32816843"],"is_preprint":false},{"year":2019,"finding":"Crystal structures of KRAS-SOS1 and SOS1 alone were determined; small-molecule inhibitors (e.g., BAY-293, IC50 21 nM) bind the SOS1 catalytic domain at the KRAS–SOS1 interface, disrupting complex formation, blocking KRAS GTP reloading, and exerting antiproliferative activity in KRAS-driven cells.","method":"X-ray crystallography, biophysical interaction assays (SPR/ITC), cellular RAS-GTP assay, antiproliferation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures plus biophysical validation plus cellular mechanistic assays, multiple orthogonal methods","pmids":["30683722"],"is_preprint":false},{"year":2018,"finding":"The crystal structure of a 14-3-3ζ dimer bound to a 13-mer SOS1 phosphopeptide motif was determined at high resolution, demonstrating that 14-3-3 proteins directly bind SOS1 at a defined PPI interface to modulate SOS1 activity in the RAS–MAPK pathway.","method":"X-ray crystallography, biochemical PPI assays","journal":"Journal of structural biology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — crystal structure with biochemical validation, single lab, functional consequence inferred from structure rather than activity assay","pmids":["29408703"],"is_preprint":false},{"year":2014,"finding":"SUMOylation of Grb2 at K56 by SUMO1 increases formation of the Grb2–SOS1 complex, leading to enhanced RAS/MEK/MAPK activation; the Grb2-K56R mutant, which cannot be SUMOylated, fails to rescue ERK activity or cell transformation when re-expressed in Grb2-knockdown cells.","method":"In vivo and in vitro SUMOylation assay, co-immunoprecipitation, ERK activation assay, cell transformation and migration assays, xenograft model","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — SUMOylation assay combined with mutagenesis rescue and co-IP, single lab, multiple functional readouts; finding concerns Grb2 modification with SOS1 as the downstream partner","pmids":["24775912"],"is_preprint":false},{"year":2016,"finding":"SOS1 mediates JAK-dependent LFA-1 activation in human T lymphocytes in response to CXCL12; SOS1 downregulation impairs rapid LFA-1-mediated adhesion, underflow arrest on ICAM-1, LFA-1 affinity triggering, and CXCL12-induced RhoA and Rac1 activation, indicating a SOS1 specificity shift to Rho-GEF activity in chemokine signaling context.","method":"siRNA knockdown of SOS1 in primary human T lymphocytes; LFA-1 adhesion assays; Rac1/RhoA-GTP pull-down; phosphotyrosine analysis; JAK inhibitor experiments","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — targeted siRNA with multiple functional and biochemical readouts, single lab","pmids":["27986909"],"is_preprint":false},{"year":2009,"finding":"Tks5/FISH interacts with SOS1 through synergistic binding of its tandem SH3A and SH3B domains to the proline-rich domain of SOS1; a splice-variant-specific basic insertion between SH3A and SH3B in the long Tks5 isoform reduces SOS1 binding affinity ~10-fold and alters recognition of SOS1 binding motifs, establishing isoform-selective SOS1 interaction.","method":"Peptide arrays, GST pulldown, isothermal titration calorimetry, analytical ultracentrifugation, co-localization in cells","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biophysical methods (ITC, AUC) plus cell co-localization, single lab; quantitative binding data supports mechanistic conclusions","pmids":["19464300"],"is_preprint":false},{"year":2017,"finding":"Phosphorylation of Y1196 on SOS1 by ABL promotes SOS1 RAC-GEF activity in vitro; the non-phosphorylatable Y1196F mutant fails to support RAC nucleotide exchange, directly linking this specific phosphorylation event to the switch in SOS1 substrate specificity from RAS-GEF to RAC-GEF.","method":"In vitro RAC nucleotide exchange assay with phosphomimetic/phospho-dead SOS1 mutants, co-IP for ABL-SOS1 interaction","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro GEF reconstitution with mutagenesis directly demonstrating mechanism, supported by in vivo co-IP and mouse leukemia model","pmids":["28819285"],"is_preprint":false},{"year":2018,"finding":"RUNX1 transcriptionally activates SOS1 expression by binding to a RUNX1-binding DNA sequence in the SOS1 promoter; RUNX1 knockdown reduces SOS1 expression and dephosphorylates ErbB2/HER2, suppressing gastric cancer cell proliferation.","method":"Promoter-binding assay (ChIP-like), RUNX1 knockdown, SOS1 mRNA/protein measurement, ErbB2 phosphorylation assay","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, RUNX1-SOS1 promoter interaction assay without full ChIP validation from abstract; knockdown data supporting regulatory link","pmids":["29686309"],"is_preprint":false},{"year":2022,"finding":"PPDPF binds GTP and transfers GTP to SOS1, enhancing SOS1 GEF activity; mutations at the PPDPF GTP-binding sites or at SOS1 residues mediating SOS1–PPDPF interaction impair SOS1 GEF activity and the tumor-promoting effects of PPDPF, defining a PPDPF–SOS1 axis for KRAS activation in pancreatic cancer.","method":"GTP-binding/transfer assay, co-immunoprecipitation, mutagenesis of interaction sites, in vitro GEF activity assay, genetic mouse PDAC model","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — GTP transfer assay plus mutagenesis plus in vitro GEF activity plus mouse model, single lab but multiple orthogonal methods","pmids":["36453576"],"is_preprint":false},{"year":2020,"finding":"High-affinity Grb2–SOS1 interaction involves nSH3 binding to the PVPPPVPPRRRP motif and cSH3 binding to the PKLPPKTYKREH motif of the SOS1 proline-rich domain; NMR data and replica-exchange simulations define the most probable Grb2–SOS1 binding mode as simultaneous engagement of both SH3 domains at distinct SOS1 sites.","method":"NMR spectroscopy with selective methyl labeling, peptide binding assays, replica-exchange molecular dynamics simulations","journal":"Journal of the American Chemical Society","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — NMR structural characterization of binding mode, single lab, functional validation limited to binding affinity measurements","pmids":["31970984"],"is_preprint":false},{"year":2021,"finding":"GRB2 displays intramolecular allostery: phosphotyrosine-peptide binding to the SH2 domain potentiates SH3 domain interactions with SOS1 (allosteric mechanism), and the SH2 domain blocks cSH3 to enable sequential nSH3-then-cSH3 binding to SOS1 (avidity-based mechanism), providing mechanistic insight into how RTK activation promotes GRB2–SOS1 complex formation.","method":"Biochemical binding assays, NMR, fluorescence polarization with phosphotyrosine peptides and SOS1 fragments","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biophysical methods characterizing allosteric mechanism, single lab","pmids":["34232285"],"is_preprint":false},{"year":2015,"finding":"Absence of both Sos1 and Sos2 in peripheral CD4+ T cells increases AKT phosphorylation upon TCR and IL-2 stimulation, likely due to increased PI3K recruitment to Grb2; this elevated PI3K/AKT activity causes downregulation of surface CD62L and impaired T-cell migration.","method":"Conditional double-knockout mice, phospho-AKT immunoblotting, PI3K–Grb2 co-immunoprecipitation, CD62L surface staining, T-cell migration assay","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean conditional DKO with biochemical co-IP evidence for mechanism, single lab","pmids":["25973715"],"is_preprint":false}],"current_model":"SOS1 is a dual guanine nucleotide exchange factor (GEF) that activates both RAS (via its CDC25 catalytic domain) and RAC (via its DH domain, triggered by ABL-mediated tyrosine phosphorylation at Y1196); it is recruited to activated receptor tyrosine kinases through Grb2 SH3–proline-rich domain interactions, and its activity is negatively regulated by MAP kinase- and RSK-mediated phosphorylation of C-terminal serines that create 14-3-3 docking sites and reduce Grb2 affinity; loss-of-function studies in mice and cells demonstrate essential roles for SOS1 in sustained EGFR-RAS-ERK signaling, early T-cell development, tight junction assembly, macrophage podosome formation, and mitochondrial redox homeostasis, while gain-of-function Noonan syndrome mutations destabilize autoinhibition to produce constitutive RAS-ERK hyperactivation."},"narrative":{"mechanistic_narrative":"SOS1 is a dual guanine nucleotide exchange factor that couples activated receptor tyrosine kinases to RAS- and RAC-family GTPases, governing proliferative signaling, cytoskeletal remodeling, and developmental cell-fate decisions [PMID:17143285, PMID:17143282, PMID:15039778, PMID:10675333]. It is recruited to activated receptors through Grb2, which simultaneously engages distinct proline-rich motifs of the SOS1 C-terminal domain via its nSH3 and cSH3 domains; phosphotyrosine binding to the Grb2 SH2 domain allosterically potentiates this interaction, providing a switch that links RTK activation to complex assembly [PMID:7520523, PMID:31970984, PMID:34232285]. Through its catalytic CDC25/REM module SOS1 loads GTP onto RAS proteins (including M-Ras) to drive ERK activation, and genetic ablation shows it is specifically required for sustained, but not transient, RAS-ERK signaling downstream of EGFR and the TCR, with RasGRP1 supplying the opposing transient and feedback-limiting arm [PMID:10675333, PMID:9030684, PMID:10446149, PMID:24497027, PMID:26005835]. A parallel RAC-GEF activity is unmasked by ABL-mediated tyrosine phosphorylation at Y1196, switching substrate specificity toward RAC and driving actin remodeling, podosome formation, and migration, and contributing to BCR-ABL leukemogenesis [PMID:15039778, PMID:26447228, PMID:28819285]. SOS1 activity is negatively regulated by MAP kinase- and RSK-mediated phosphorylation of C-terminal serines, which reduces Grb2 affinity and creates 14-3-3 docking sites, constituting a negative feedback loop on the pathway [PMID:8816480, PMID:22827337, PMID:29408703]. SOS1 also supports tight junction assembly, early T-cell development, and mitochondrial redox homeostasis, and acts as a GEF-independent scaffold in EGFR-NFκB signaling [PMID:21746917, PMID:25071181, PMID:25394671, PMID:27157612]. Gain-of-function mutations that destabilize autoinhibition cause Noonan syndrome, a truncating mutation removing the C-terminal proline-rich domains causes hereditary gingival fibromatosis, and the catalytic SOS1-KRAS interface defined by crystal structures is a validated drug target [PMID:17143285, PMID:17143282, PMID:11868160, PMID:17510059, PMID:32816843, PMID:30683722].","teleology":[{"year":1994,"claim":"Established how SOS1 is recruited to activated receptors, answering whether it engages receptors directly or via an adaptor.","evidence":"Co-immunoprecipitation and SH2/SH3 domain-binding assays in M-CSF-stimulated myeloid cells","pmids":["7520523"],"confidence":"Medium","gaps":["Did not resolve the precise SH3 motifs or stoichiometry of Grb2-SOS1 binding","Receptor specificity beyond Fms not addressed"]},{"year":1996,"claim":"Defined a negative-regulatory mechanism on SOS1 by mapping MAP kinase phosphosites in the proline-rich domain and linking them to Grb2 affinity.","evidence":"Site-directed mutagenesis with in vitro phosphorylation and Grb2 binding affinity measurements","pmids":["8816480"],"confidence":"High","gaps":["Did not establish in vivo kinetics of feedback","Cellular consequence for ERK output not measured directly"]},{"year":1997,"claim":"Demonstrated an in vivo genetic requirement for SOS1 in EGFR signaling, moving beyond biochemical association to organismal epistasis.","evidence":"Sos1/EGFR double-mutant mice and ERK assays in null fibroblasts","pmids":["9030684"],"confidence":"High","gaps":["Mechanistic basis of embryonic lethality not dissected","Did not distinguish transient vs sustained signaling roles"]},{"year":1999,"claim":"Extended SOS1 substrate scope by showing GEF activity toward M-Ras in addition to classical RAS.","evidence":"In vitro GDP/GTP exchange assay, yeast two-hybrid, co-IP","pmids":["10446149"],"confidence":"Medium","gaps":["Physiological relevance of M-Ras GEF activity unclear","Single-lab biochemistry"]},{"year":2000,"claim":"Showed SOS1 specifically supports sustained rather than transient RAS-ERK signaling, distinguishing it from Sos2.","evidence":"Sos1 knockout mice and ERK time-course in null cells with transformation assays","pmids":["10675333"],"confidence":"High","gaps":["Molecular basis of the sustained-vs-transient distinction not defined","Placental phenotype mechanism unresolved"]},{"year":2001,"claim":"Identified V-ATPase E as a positive regulator of SOS1 RAC-GEF activity at endosomes, implicating subcellular localization in pathway control.","evidence":"Affinity purification, yeast two-hybrid, co-IP, fractionation, in vitro Rac1-GEF assay","pmids":["11560919"],"confidence":"Medium","gaps":["In vivo significance of endosomal SOS1-Rac1 not established","Single lab"]},{"year":2004,"claim":"Revealed that SOS1 is a RAC-GEF activated by ABL tyrosine phosphorylation, defining a second signaling output for actin remodeling.","evidence":"In vitro RAC-GEF assay, co-IP, pharmacological/genetic ABL inhibition","pmids":["15039778"],"confidence":"High","gaps":["Specific phosphosite not yet mapped","Coupling between RAS and RAC arms not resolved"]},{"year":2006,"claim":"Established SOS1 as a Noonan syndrome disease gene with a gain-of-function mechanism via disrupted autoinhibition.","evidence":"Genetic mapping in patients and ectopic expression of mutants with RAS/ERK readouts","pmids":["17143285","17143282"],"confidence":"High","gaps":["Structural detail of autoinhibition release not resolved here","Tissue-specific consequences not addressed"]},{"year":2002,"claim":"Linked a SOS1 C-terminal truncating mutation to hereditary gingival fibromatosis, implicating loss of proline-rich regulatory domains in disease.","evidence":"Positional cloning and segregation analysis across four generations","pmids":["11868160"],"confidence":"Medium","gaps":["Functional consequence inferred from analogous transgenic data, not tested here"]},{"year":2007,"claim":"Provided the mechanism by which the HGF1 truncated SOS1 drives proliferation, showing constitutive membrane localization and cell-cycle entry.","evidence":"Ectopic expression, siRNA, ERK and cell-cycle marker immunoblotting","pmids":["17510059"],"confidence":"Medium","gaps":["Membrane-targeting mechanism of the truncated protein not defined","Single-lab cell-based study"]},{"year":2010,"claim":"Defined a SOS1/EPS8/ABI1 tri-complex required for Rac-driven migration and metastasis, placing SOS1 in a cytoskeletal effector module.","evidence":"Reciprocal co-IP, knockdown, rescue, Rac-GTP and in vivo peritoneal colonization assays","pmids":["21118970"],"confidence":"High","gaps":["Assembly hierarchy of the complex not fully resolved","Upstream activating signal incompletely defined"]},{"year":2011,"claim":"Showed stage-specific requirement for SOS1 in pre-TCR but not TCR signaling during T-cell development.","evidence":"Conditional knockout mice with thymocyte subset and ERK analysis","pmids":["21746917"],"confidence":"High","gaps":["Molecular basis of pre-TCR vs TCR selectivity unresolved"]},{"year":2012,"claim":"Identified RSK as a kinase generating 14-3-3 docking sites on SOS1, defining a negative feedback loop restraining MAPK signaling.","evidence":"Quantitative MS, RSK inhibition, mutagenesis, 14-3-3 binding and ERK time-course","pmids":["22827337"],"confidence":"High","gaps":["Magnitude of feedback in vivo modest","Interplay with MAP kinase phosphosites not integrated"]},{"year":2013,"claim":"Demonstrated cooperative multivalent SOS1/Grb2 engagement as a threshold mechanism for FGF-driven lineage commitment.","evidence":"Domain mutagenesis, interaction assays, ES cell differentiation and rescue","pmids":["23452850"],"confidence":"High","gaps":["Quantitative threshold parameters not defined","Phospholipid contribution mechanistically incomplete"]},{"year":2014,"claim":"Expanded SOS1 roles to GEF-independent scaffolding (EGFR-NFκB), tight junction assembly via EMP1, sustained TCR ERK signaling, and Grb2-SUMOylation-dependent complex formation.","evidence":"RNAi, overexpression, GEF-dead mutants, microarray, reporter, and SUMOylation assays across multiple cell systems","pmids":["25071181","25394671","24497027","24775912"],"confidence":"Medium","gaps":["Scaffolding partners in NFκB pathway not identified","Direct SOS1 role vs downstream EMP1 effect not fully separated"]},{"year":2015,"claim":"Defined SOS1 opposition to RasGRP1 in EGFR-RAS signaling and revealed loss of Sos restrains PI3K/AKT in T cells.","evidence":"Genetic mouse models with KRas/Apc mutations; conditional DKO T cells with phospho-AKT and migration assays","pmids":["26005835","25973715"],"confidence":"High","gaps":["Molecular basis of SOS1/RasGRP1 functional partitioning unresolved"]},{"year":2015,"claim":"Placed SOS1 at macrophage podosomes as a Src/ABL-regulated Rac-GEF driving matrix degradation and invasion.","evidence":"siRNA, co-IP, Rac-GTP pulldown, invasion assays, live-cell imaging","pmids":["26447228"],"confidence":"Medium","gaps":["Distinct contributions of Src vs ABL phosphorylation not separated"]},{"year":2016,"claim":"Linked SOS1 to mitochondrial redox homeostasis, showing its loss elevates ROS and mitophagy with antioxidant-rescuable phenotypes.","evidence":"Inducible Sos1-null MEFs, EM, ROS assays, antioxidant rescue","pmids":["27157612"],"confidence":"High","gaps":["Whether redox role is GEF-dependent not determined","Mechanism connecting SOS1 to mitochondria unknown"]},{"year":2017,"claim":"Pinpointed Y1196 as the ABL phosphosite that switches SOS1 to RAC-GEF activity and drives BCR-ABL leukemogenesis.","evidence":"In vitro RAC-GEF assay with phospho-Y1196 mutants, co-IP, Sos1 conditional KO, leukemia models","pmids":["28819285"],"confidence":"High","gaps":["Structural basis of the specificity switch not resolved"]},{"year":2018,"claim":"Provided structural detail of regulatory interfaces, including 14-3-3 binding to a SOS1 phosphopeptide, and a transcriptional regulator (RUNX1) driving SOS1 expression.","evidence":"X-ray crystallography of 14-3-3ζ-SOS1 peptide; RUNX1 promoter-binding and knockdown assays","pmids":["29408703","29686309"],"confidence":"Medium","gaps":["RUNX1-SOS1 link is Low-confidence without full ChIP validation","Functional consequence of 14-3-3 binding inferred from structure"]},{"year":2019,"claim":"Validated SOS1 catalytic domain as a druggable KRAS interface and confirmed cancer-derived SOS1 mutations as oncogenic gain-of-function.","evidence":"Crystal structures of KRAS-SOS1, BAY-293 inhibitor characterization, and ectopic expression of lung adenocarcinoma mutants with xenografts","pmids":["30683722","30635434"],"confidence":"High","gaps":["Allosteric vs catalytic-site inhibitor selectivity across SOS isoforms not fully resolved"]},{"year":2020,"claim":"Defined the high-affinity Grb2-SOS1 binding mode and a clinical-grade catalytic-site inhibitor (BI-3406) that blocks feedback reactivation.","evidence":"NMR and REMD of Grb2-SOS1; crystal structures and cellular RAS-GTP assays with BI-3406","pmids":["31970984","32816843"],"confidence":"Medium","gaps":["In vivo durability of inhibition not addressed in these studies"]},{"year":2021,"claim":"Revealed the allosteric/avidity logic by which GRB2 SH2 phosphotyrosine binding couples RTK activation to SOS1 engagement.","evidence":"Biochemical, NMR, and fluorescence polarization assays with phosphopeptides and SOS1 fragments","pmids":["34232285"],"confidence":"Medium","gaps":["Cellular dynamics of the allosteric switch not measured"]},{"year":2022,"claim":"Identified PPDPF as a GTP-supplying cofactor that enhances SOS1 GEF activity, adding a new layer to KRAS activation in pancreatic cancer.","evidence":"GTP-binding/transfer assay, co-IP, mutagenesis, in vitro GEF assay, PDAC mouse model","pmids":["36453576"],"confidence":"Medium","gaps":["Generality of the PPDPF-SOS1 axis beyond pancreatic cancer unclear"]},{"year":null,"claim":"How SOS1 mechanistically controls mitochondrial redox state, and whether its non-canonical scaffolding and Rho-GEF functions are GEF-domain-independent, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No mechanism connecting SOS1 to mitochondrial ROS established","Structural basis for RAS-vs-RAC substrate switching not defined","GEF-independent functions lack defined molecular partners"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[0,4,12,23,24]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,17,21,29]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,14,32]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,4,20]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[7,17]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[21]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[8,17,18]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,4,5,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,6,22,23]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,15,27,34]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[11,4,5]}],"complexes":["Grb2-SOS1 complex","SOS1/EPS8/ABI1 complex"],"partners":["GRB2","ABL1","EPS8","ABI1","PLCG1","14-3-3","PPDPF","TKS5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q07889","full_name":"Son of sevenless homolog 1","aliases":[],"length_aa":1333,"mass_kda":152.5,"function":"Promotes the exchange of Ras-bound GDP by GTP (PubMed:8493579). Probably by promoting Ras activation, regulates phosphorylation of MAP kinase MAPK3/ERK1 in response to EGF (PubMed:17339331). Catalytic component of a trimeric complex that participates in transduction of signals from Ras to Rac by promoting the Rac-specific guanine nucleotide exchange factor (GEF) activity (By similarity)","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/Q07889/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SOS1","classification":"Not Classified","n_dependent_lines":222,"n_total_lines":1208,"dependency_fraction":0.1837748344370861},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000115904","cell_line_id":"CID000604","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":1}],"interactors":[{"gene":"CAPZB","stoichiometry":0.2},{"gene":"CETN3","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000604","total_profiled":1310},"omim":[{"mim_id":"619455","title":"SH3 AND PX DOMAINS-CONTAINING PROTEIN 2A; SH3PXD2A","url":"https://www.omim.org/entry/619455"},{"mim_id":"617626","title":"FIBROMATOSIS, GINGIVAL, 5; GINGF5","url":"https://www.omim.org/entry/617626"},{"mim_id":"616559","title":"NOONAN SYNDROME 9; NS9","url":"https://www.omim.org/entry/616559"},{"mim_id":"615355","title":"NOONAN SYNDROME 8; NS8","url":"https://www.omim.org/entry/615355"},{"mim_id":"614989","title":"EPS8-LIKE PROTEIN 3; EPS8L3","url":"https://www.omim.org/entry/614989"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SOS1"},"hgnc":{"alias_symbol":["HGF","GF1"],"prev_symbol":["GINGF"]},"alphafold":{"accession":"Q07889","domains":[{"cath_id":"1.10.20.10","chopping":"16-177","consensus_level":"high","plddt":83.8166,"start":16,"end":177},{"cath_id":"1.20.900.10","chopping":"202-409","consensus_level":"medium","plddt":90.2059,"start":202,"end":409},{"cath_id":"2.30.29.30","chopping":"414-477_486-566","consensus_level":"medium","plddt":84.2364,"start":414,"end":566},{"cath_id":"1.20.870.10","chopping":"577-655_674-747","consensus_level":"medium","plddt":90.0156,"start":577,"end":747},{"cath_id":"1.10.840.10","chopping":"772-930_979-1017","consensus_level":"high","plddt":95.7263,"start":772,"end":1017}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07889","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q07889-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q07889-F1-predicted_aligned_error_v6.png","plddt_mean":76.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SOS1","jax_strain_url":"https://www.jax.org/strain/search?query=SOS1"},"sequence":{"accession":"Q07889","fasta_url":"https://rest.uniprot.org/uniprotkb/Q07889.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q07889/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07889"}},"corpus_meta":[{"pmid":"17143285","id":"PMC_17143285","title":"Germline gain-of-function mutations in SOS1 cause Noonan syndrome.","date":"2006","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17143285","citation_count":449,"is_preprint":false},{"pmid":"17143282","id":"PMC_17143282","title":"Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome.","date":"2006","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17143282","citation_count":431,"is_preprint":false},{"pmid":"32816843","id":"PMC_32816843","title":"BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.","date":"2020","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/32816843","citation_count":345,"is_preprint":false},{"pmid":"12239394","id":"PMC_12239394","title":"SOS1, a Genetic Locus Essential for Salt Tolerance and Potassium Acquisition.","date":"1996","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/12239394","citation_count":327,"is_preprint":false},{"pmid":"30683722","id":"PMC_30683722","title":"Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30683722","citation_count":314,"is_preprint":false},{"pmid":"19571313","id":"PMC_19571313","title":"Loss of halophytism by interference with SOS1 expression.","date":"2009","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19571313","citation_count":170,"is_preprint":false},{"pmid":"11868160","id":"PMC_11868160","title":"A mutation in the SOS1 gene causes hereditary gingival fibromatosis type 1.","date":"2002","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11868160","citation_count":159,"is_preprint":false},{"pmid":"8816480","id":"PMC_8816480","title":"Identification of the mitogen-activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8816480","citation_count":152,"is_preprint":false},{"pmid":"7520523","id":"PMC_7520523","title":"Shc, Grb2, Sos1, and a 150-kilodalton tyrosine-phosphorylated protein form complexes with Fms in hematopoietic cells.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7520523","citation_count":126,"is_preprint":false},{"pmid":"15039778","id":"PMC_15039778","title":"Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation.","date":"2004","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15039778","citation_count":114,"is_preprint":false},{"pmid":"10446149","id":"PMC_10446149","title":"M-Ras/R-Ras3, a transforming ras protein regulated by Sos1, GRF1, and p120 Ras GTPase-activating protein, interacts with the putative Ras effector AF6.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10446149","citation_count":102,"is_preprint":false},{"pmid":"21387466","id":"PMC_21387466","title":"SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations.","date":"2011","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/21387466","citation_count":99,"is_preprint":false},{"pmid":"10675333","id":"PMC_10675333","title":"The Sos1 and Sos2 Ras-specific exchange factors: differences in placental expression and signaling properties.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10675333","citation_count":96,"is_preprint":false},{"pmid":"17586837","id":"PMC_17586837","title":"SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome.","date":"2007","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17586837","citation_count":95,"is_preprint":false},{"pmid":"20054031","id":"PMC_20054031","title":"Intracellular consequences of SOS1 deficiency during salt stress.","date":"2010","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/20054031","citation_count":95,"is_preprint":false},{"pmid":"19020799","id":"PMC_19020799","title":"PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.","date":"2008","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19020799","citation_count":82,"is_preprint":false},{"pmid":"21118970","id":"PMC_21118970","title":"Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21118970","citation_count":79,"is_preprint":false},{"pmid":"33219052","id":"PMC_33219052","title":"Severe Lymphatic Disorder Resolved With MEK Inhibition in a Patient With Noonan Syndrome and SOS1 Mutation.","date":"2020","source":"Pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/33219052","citation_count":77,"is_preprint":false},{"pmid":"35833726","id":"PMC_35833726","title":"Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35833726","citation_count":76,"is_preprint":false},{"pmid":"28450879","id":"PMC_28450879","title":"SOS1, HKT1;5, and NHX1 Synergistically Modulate Na+ Homeostasis in the Halophytic Grass Puccinellia tenuiflora.","date":"2017","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/28450879","citation_count":73,"is_preprint":false},{"pmid":"26585227","id":"PMC_26585227","title":"Nax loci affect SOS1-like Na+/H+ exchanger expression and activity in wheat.","date":"2015","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/26585227","citation_count":71,"is_preprint":false},{"pmid":"22827337","id":"PMC_22827337","title":"RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation.","date":"2012","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/22827337","citation_count":71,"is_preprint":false},{"pmid":"39814877","id":"PMC_39814877","title":"Elemental cryo-imaging reveals SOS1-dependent vacuolar sodium accumulation.","date":"2025","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/39814877","citation_count":63,"is_preprint":false},{"pmid":"26005835","id":"PMC_26005835","title":"RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.","date":"2015","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26005835","citation_count":62,"is_preprint":false},{"pmid":"9030684","id":"PMC_9030684","title":"Mutation in Sos1 dominantly enhances a weak allele of the EGFR, demonstrating a requirement for Sos1 in EGFR signaling and development.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9030684","citation_count":62,"is_preprint":false},{"pmid":"19953625","id":"PMC_19953625","title":"Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations.","date":"2010","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19953625","citation_count":60,"is_preprint":false},{"pmid":"19724911","id":"PMC_19724911","title":"Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men.","date":"2009","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19724911","citation_count":57,"is_preprint":false},{"pmid":"37884653","id":"PMC_37884653","title":"Structure and activation mechanism of the rice Salt Overly Sensitive 1 (SOS1) Na+/H+ antiporter.","date":"2023","source":"Nature plants","url":"https://pubmed.ncbi.nlm.nih.gov/37884653","citation_count":55,"is_preprint":false},{"pmid":"21746917","id":"PMC_21746917","title":"Targeted Sos1 deletion reveals its critical role in early T-cell development.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21746917","citation_count":55,"is_preprint":false},{"pmid":"24775912","id":"PMC_24775912","title":"SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1.","date":"2014","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24775912","citation_count":55,"is_preprint":false},{"pmid":"23452850","id":"PMC_23452850","title":"Interaction domains of Sos1/Grb2 are finely tuned for cooperative control of embryonic stem cell fate.","date":"2013","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/23452850","citation_count":54,"is_preprint":false},{"pmid":"33719426","id":"PMC_33719426","title":"One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.","date":"2021","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33719426","citation_count":52,"is_preprint":false},{"pmid":"10913276","id":"PMC_10913276","title":"Direct interaction of SOS1 Ras exchange protein with the SH3 domain of phospholipase C-gamma1.","date":"2000","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10913276","citation_count":51,"is_preprint":false},{"pmid":"24043312","id":"PMC_24043312","title":"Functional redundancy of Sos1 and Sos2 for lymphopoiesis and organismal homeostasis and survival.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24043312","citation_count":49,"is_preprint":false},{"pmid":"25071181","id":"PMC_25071181","title":"EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25071181","citation_count":48,"is_preprint":false},{"pmid":"25455859","id":"PMC_25455859","title":"Rational design of small molecule inhibitors targeting the Ras GEF, SOS1.","date":"2014","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/25455859","citation_count":48,"is_preprint":false},{"pmid":"25804817","id":"PMC_25804817","title":"Constitutive high-level SOS1 expression and absence of HKT1;1 expression in the salt-accumulating halophyte Salicornia dolichostachya.","date":"2015","source":"Plant science : an international journal of experimental plant biology","url":"https://pubmed.ncbi.nlm.nih.gov/25804817","citation_count":46,"is_preprint":false},{"pmid":"31901205","id":"PMC_31901205","title":"The plasma-membrane polyamine transporter PUT3 is regulated by the Na+ /H+ antiporter SOS1 and protein kinase SOS2.","date":"2020","source":"The New phytologist","url":"https://pubmed.ncbi.nlm.nih.gov/31901205","citation_count":45,"is_preprint":false},{"pmid":"19767895","id":"PMC_19767895","title":"Characterization of Salt Overly Sensitive 1 (SOS1) gene homoeologs in quinoa (Chenopodium quinoa Willd.).","date":"2009","source":"Genome","url":"https://pubmed.ncbi.nlm.nih.gov/19767895","citation_count":45,"is_preprint":false},{"pmid":"36459180","id":"PMC_36459180","title":"Development of SOS1 Inhibitor-Based Degraders to Target KRAS-Mutant Colorectal Cancer.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36459180","citation_count":44,"is_preprint":false},{"pmid":"19352411","id":"PMC_19352411","title":"SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions.","date":"2009","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/19352411","citation_count":40,"is_preprint":false},{"pmid":"20696009","id":"PMC_20696009","title":"The SOS1 transporter of Physcomitrella patens mediates sodium efflux in planta.","date":"2010","source":"The New phytologist","url":"https://pubmed.ncbi.nlm.nih.gov/20696009","citation_count":40,"is_preprint":false},{"pmid":"18064648","id":"PMC_18064648","title":"SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.","date":"2008","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18064648","citation_count":38,"is_preprint":false},{"pmid":"24497027","id":"PMC_24497027","title":"Sos1 regulates sustained TCR-mediated Erk activation.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24497027","citation_count":37,"is_preprint":false},{"pmid":"27157612","id":"PMC_27157612","title":"Sos1 disruption impairs cellular proliferation and viability through an increase in mitochondrial oxidative stress in primary MEFs.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27157612","citation_count":37,"is_preprint":false},{"pmid":"22404736","id":"PMC_22404736","title":"Isolation and characterisation of Chrysanthemum crassum SOS1, encoding a putative plasma membrane Na(+) /H(+) antiporter.","date":"2012","source":"Plant biology (Stuttgart, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/22404736","citation_count":37,"is_preprint":false},{"pmid":"17510059","id":"PMC_17510059","title":"Germ line gain of function with SOS1 mutation in hereditary gingival fibromatosis.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17510059","citation_count":36,"is_preprint":false},{"pmid":"29686309","id":"PMC_29686309","title":"RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29686309","citation_count":35,"is_preprint":false},{"pmid":"20461756","id":"PMC_20461756","title":"Noonan syndrome, the SOS1 gene and embryonal rhabdomyosarcoma.","date":"2010","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20461756","citation_count":33,"is_preprint":false},{"pmid":"28060514","id":"PMC_28060514","title":"Targeted Covalent Inhibition of Grb2-Sos1 Interaction through Proximity-Induced Conjugation in Breast Cancer Cells.","date":"2017","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/28060514","citation_count":33,"is_preprint":false},{"pmid":"31970984","id":"PMC_31970984","title":"High-Affinity Interactions of the nSH3/cSH3 Domains of Grb2 with the C-Terminal Proline-Rich Domain of SOS1.","date":"2020","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/31970984","citation_count":33,"is_preprint":false},{"pmid":"30635434","id":"PMC_30635434","title":"Identification and Characterization of Oncogenic SOS1 Mutations in Lung Adenocarcinoma.","date":"2019","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/30635434","citation_count":32,"is_preprint":false},{"pmid":"37626035","id":"PMC_37626035","title":"EIF4A3-mediated circ_0042881 activates the RAS pathway via miR-217/SOS1 axis to facilitate breast cancer progression.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37626035","citation_count":32,"is_preprint":false},{"pmid":"28819285","id":"PMC_28819285","title":"Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.","date":"2017","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/28819285","citation_count":32,"is_preprint":false},{"pmid":"38769297","id":"PMC_38769297","title":"SOS1 tonoplast neo-localization and the RGG protein SALTY are important in the extreme salinity tolerance of Salicornia bigelovii.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38769297","citation_count":30,"is_preprint":false},{"pmid":"30669571","id":"PMC_30669571","title":"Fucoidan⁻Fucoxanthin Ameliorated Cardiac Function via IRS1/GRB2/ SOS1, GSK3β/CREB Pathways and Metabolic Pathways in Senescent Mice.","date":"2019","source":"Marine drugs","url":"https://pubmed.ncbi.nlm.nih.gov/30669571","citation_count":30,"is_preprint":false},{"pmid":"25469565","id":"PMC_25469565","title":"miR-146a and miR-370 coordinate enterovirus 71-induced cell apoptosis through targeting SOS1 and GADD45β.","date":"2015","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/25469565","citation_count":29,"is_preprint":false},{"pmid":"30233203","id":"PMC_30233203","title":"MicroRNA 628 suppresses migration and invasion of breast cancer stem cells through targeting SOS1.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30233203","citation_count":29,"is_preprint":false},{"pmid":"37972068","id":"PMC_37972068","title":"SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37972068","citation_count":28,"is_preprint":false},{"pmid":"38904222","id":"PMC_38904222","title":"The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.","date":"2024","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38904222","citation_count":28,"is_preprint":false},{"pmid":"10995566","id":"PMC_10995566","title":"Refinement of the locus for autosomal dominant hereditary gingival fibromatosis (GINGF) to a 3.8-cM region on 2p21.","date":"2000","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10995566","citation_count":28,"is_preprint":false},{"pmid":"25394671","id":"PMC_25394671","title":"SOS1 and Ras regulate epithelial tight junction formation in the human airway through EMP1.","date":"2014","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/25394671","citation_count":26,"is_preprint":false},{"pmid":"36173339","id":"PMC_36173339","title":"Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36173339","citation_count":25,"is_preprint":false},{"pmid":"20389169","id":"PMC_20389169","title":"Decreased expression of FGFR1, SOS1, RAF1 genes in cryptorchidism.","date":"2010","source":"Urologia internationalis","url":"https://pubmed.ncbi.nlm.nih.gov/20389169","citation_count":25,"is_preprint":false},{"pmid":"33446575","id":"PMC_33446575","title":"Epigenetic and Posttranscriptional Modulation of SOS1 Can Promote Breast Cancer Metastasis through Obesity-Activated c-Met Signaling in African-American Women.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33446575","citation_count":25,"is_preprint":false},{"pmid":"33760128","id":"PMC_33760128","title":"lncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR‑20b‑5p/SOS1 axis.","date":"2021","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33760128","citation_count":25,"is_preprint":false},{"pmid":"25980493","id":"PMC_25980493","title":"Nuclear EGFR impairs ASPP2-p53 complex-induced apoptosis by inducing SOS1 expression in hepatocellular carcinoma.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25980493","citation_count":25,"is_preprint":false},{"pmid":"30258545","id":"PMC_30258545","title":"Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS.","date":"2018","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/30258545","citation_count":25,"is_preprint":false},{"pmid":"35101230","id":"PMC_35101230","title":"Targeting RAS oncogenesis with SOS1 inhibitors.","date":"2021","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35101230","citation_count":24,"is_preprint":false},{"pmid":"38630077","id":"PMC_38630077","title":"Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38630077","citation_count":24,"is_preprint":false},{"pmid":"34232285","id":"PMC_34232285","title":"The intramolecular allostery of GRB2 governing its interaction with SOS1 is modulated by phosphotyrosine ligands.","date":"2021","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/34232285","citation_count":24,"is_preprint":false},{"pmid":"8649846","id":"PMC_8649846","title":"Sos1 rapidly associates with Grb2 and is hypophosphorylated when complexed with the EGF receptor after EGF stimulation.","date":"1996","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8649846","citation_count":24,"is_preprint":false},{"pmid":"32673492","id":"PMC_32673492","title":"Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based Methods.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32673492","citation_count":24,"is_preprint":false},{"pmid":"26447228","id":"PMC_26447228","title":"Sos1 Regulates Macrophage Podosome Assembly and Macrophage Invasive Capacity.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26447228","citation_count":23,"is_preprint":false},{"pmid":"11560919","id":"PMC_11560919","title":"The Sos1-Rac1 signaling. Possible involvement of a vacuolar H(+)-ATPase E subunit.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11560919","citation_count":23,"is_preprint":false},{"pmid":"34252347","id":"PMC_34252347","title":"Salicylic acid modulates ACS, NHX1, sos1 and HKT1;2 expression to regulate ethylene overproduction and Na+ ions toxicity that leads to improved physiological status and enhanced salinity stress tolerance in tomato plants cv. Pusa Ruby.","date":"2021","source":"Plant signaling & behavior","url":"https://pubmed.ncbi.nlm.nih.gov/34252347","citation_count":23,"is_preprint":false},{"pmid":"25973715","id":"PMC_25973715","title":"Absence of both Sos-1 and Sos-2 in peripheral CD4(+) T cells leads to PI3K pathway activation and defects in migration.","date":"2015","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25973715","citation_count":23,"is_preprint":false},{"pmid":"36987571","id":"PMC_36987571","title":"Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling.","date":"2023","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36987571","citation_count":22,"is_preprint":false},{"pmid":"32413671","id":"PMC_32413671","title":"miR-429-CRKL axis regulates clear cell renal cell carcinoma malignant progression through SOS1/MEK/ERK/MMP2/MMP9 pathway.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32413671","citation_count":22,"is_preprint":false},{"pmid":"31678368","id":"PMC_31678368","title":"Expression and detergent free purification and reconstitution of the plant plasma membrane Na+/H+ antiporter SOS1 overexpressed in Pichia pastoris.","date":"2019","source":"Biochimica et biophysica acta. Biomembranes","url":"https://pubmed.ncbi.nlm.nih.gov/31678368","citation_count":22,"is_preprint":false},{"pmid":"36048281","id":"PMC_36048281","title":"Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines.","date":"2022","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36048281","citation_count":22,"is_preprint":false},{"pmid":"35041140","id":"PMC_35041140","title":"Knockdown of circRNA-Memo1 Reduces Hypoxia/Reoxygenation Injury in Human Brain Endothelial Cells Through miRNA-17-5p/SOS1 Axis.","date":"2022","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/35041140","citation_count":22,"is_preprint":false},{"pmid":"29408703","id":"PMC_29408703","title":"Structural characterization of 14-3-3ζ in complex with the human Son of sevenless homolog 1 (SOS1).","date":"2018","source":"Journal of structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/29408703","citation_count":22,"is_preprint":false},{"pmid":"36793426","id":"PMC_36793426","title":"Design, Synthesis, and Bioevaluation of Pyrido[2,3-d]pyrimidin-7-ones as Potent SOS1 Inhibitors.","date":"2023","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/36793426","citation_count":20,"is_preprint":false},{"pmid":"36077294","id":"PMC_36077294","title":"Comparing Essentiality of SOS1-Mediated Na+ Exclusion in Salinity Tolerance between Cultivated and Wild Rice Species.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36077294","citation_count":19,"is_preprint":false},{"pmid":"27986909","id":"PMC_27986909","title":"SOS1, ARHGEF1, and DOCK2 rho-GEFs Mediate JAK-Dependent LFA-1 Activation by Chemokines.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27986909","citation_count":17,"is_preprint":false},{"pmid":"29394412","id":"PMC_29394412","title":"Footprints of divergent evolution in two Na+/H+ type antiporter gene families (NHX and SOS1) in the genus Populus.","date":"2018","source":"Tree physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29394412","citation_count":17,"is_preprint":false},{"pmid":"22396725","id":"PMC_22396725","title":"Modeling and simulation of aggregation of membrane protein LAT with molecular variability in the number of binding sites for cytosolic Grb2-SOS1-Grb2.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22396725","citation_count":17,"is_preprint":false},{"pmid":"36403479","id":"PMC_36403479","title":"SOS1 regulates HCC cell epithelial-mesenchymal transition via the PI3K/AKT/mTOR pathway.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/36403479","citation_count":16,"is_preprint":false},{"pmid":"19464300","id":"PMC_19464300","title":"Isoform-selective interaction of the adaptor protein Tks5/FISH with Sos1 and dynamins.","date":"2009","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19464300","citation_count":16,"is_preprint":false},{"pmid":"32397251","id":"PMC_32397251","title":"14-3-3 Proteins and Other Candidates form Protein-Protein Interactions with the Cytosolic C-terminal End of SOS1 Affecting Its Transport Activity.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32397251","citation_count":16,"is_preprint":false},{"pmid":"30735352","id":"PMC_30735352","title":"Small Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling via Independent Cellular Responses.","date":"2019","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/30735352","citation_count":15,"is_preprint":false},{"pmid":"31488087","id":"PMC_31488087","title":"Inhibitory short peptides targeting EPS8/ABI1/SOS1 tri-complex suppress invasion and metastasis of ovarian cancer cells.","date":"2019","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31488087","citation_count":15,"is_preprint":false},{"pmid":"38316747","id":"PMC_38316747","title":"A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38316747","citation_count":14,"is_preprint":false},{"pmid":"36453576","id":"PMC_36453576","title":"PPDPF Promotes the Development of Mutant KRAS-Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36453576","citation_count":14,"is_preprint":false},{"pmid":"31807027","id":"PMC_31807027","title":"miR-152-3p Sensitizes Glioblastoma Cells Towards Cisplatin Via Regulation Of SOS1.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31807027","citation_count":14,"is_preprint":false},{"pmid":"39437166","id":"PMC_39437166","title":"SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.","date":"2025","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/39437166","citation_count":13,"is_preprint":false},{"pmid":"25712082","id":"PMC_25712082","title":"Differential allelic expression of SOS1 and hyperexpression of the activating SOS1 c.755C variant in a Noonan syndrome family.","date":"2015","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/25712082","citation_count":13,"is_preprint":false},{"pmid":"33889087","id":"PMC_33889087","title":"Sos1 Modulates Extracellular Matrix Synthesis, Proliferation, and Migration in Fibroblasts.","date":"2021","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33889087","citation_count":13,"is_preprint":false},{"pmid":"31368652","id":"PMC_31368652","title":"SOS1 mutations in Noonan syndrome: Cardiomyopathies and not only congenital heart defects! Report of six patients including two novel variants and literature review.","date":"2019","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/31368652","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50517,"output_tokens":9028,"usd":0.143485,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19048,"output_tokens":6619,"usd":0.130357,"stage2_stop_reason":"end_turn"},"total_usd":0.273842,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"Missense mutations in SOS1 that cluster at residues maintaining autoinhibition cause Noonan syndrome by acting as hypermorphs: ectopic expression of two Noonan syndrome-associated SOS1 mutants enhances RAS and ERK activation, identifying SOS1 as a RAS guanine nucleotide exchange factor whose gain-of-function causes disease.\",\n      \"method\": \"Ectopic expression of mutant SOS1 constructs in cell lines with RAS-GTP and ERK activation readouts; genetic mapping in human patients\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated independently in two simultaneous papers (PMID:17143285 and PMID:17143282) using ectopic expression and biochemical readouts, with structural/domain inference supported by both studies\",\n      \"pmids\": [\"17143285\", \"17143282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"MAP kinase phosphorylates human SOS1 on five C-terminal serine residues (S1137, S1167, S1178, S1193, S1197) clustered within the proline-rich SH3-binding domain; replacing four of these sites with alanine increases Grb2 binding affinity, indicating that MAP kinase-mediated phosphorylation negatively regulates Grb2–SOS1 interaction and thereby modulates RAS activation.\",\n      \"method\": \"Site-directed mutagenesis combined with in vitro phosphorylation assays and Grb2 binding affinity measurements\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis of specific phosphorylation sites with direct binding affinity measurements, multiple orthogonal methods in one study\",\n      \"pmids\": [\"8816480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"After M-CSF stimulation, SOS1 forms complexes with Grb2 and the Fms receptor (M-CSF receptor) in myeloid cells; SOS1 also co-immunoprecipitates with Shc, and neither Grb2 nor SOS1 in these complexes contains phosphotyrosine, indicating SOS1 is recruited to the activated receptor via Grb2 adaptor interactions.\",\n      \"method\": \"Co-immunoprecipitation and SH2/SH3 domain-binding assays in M-CSF-stimulated myeloid progenitor cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP with domain-binding confirmation, single lab but multiple orthogonal binding assays\",\n      \"pmids\": [\"7520523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The non-receptor tyrosine kinase Abl phosphorylates SOS1 on tyrosine after RTK activation; Abl-induced tyrosine phosphorylation of SOS1 is sufficient to elicit its RAC-GEF activity in vitro, and SOS1 interacts with Abl in vivo, defining an RTK–Abl–SOS1–Rac pathway for actin remodeling.\",\n      \"method\": \"In vitro RAC-GEF activity assay, co-immunoprecipitation, pharmacological and genetic Abl inhibition\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro GEF reconstitution assay plus co-IP plus genetic/pharmacological interference, multiple orthogonal methods in one study\",\n      \"pmids\": [\"15039778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Targeted disruption of mouse sos1 causes mid-gestational embryonic lethality due to impaired placental trophoblast development with very low ERK activity; sos1-null cells show reduced transformation by v-Src or overexpressed EGFR and reduced long-term ERK activation, whereas Sos2 compensates only for short-term signaling, demonstrating that SOS1 is specifically required for sustained RAS–ERK signaling downstream of EGFR.\",\n      \"method\": \"Homologous recombination knockout mice; transformation assays; ERK activation time-course in sos1−/− cell lines\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with multiple defined cellular phenotypes and mechanistic comparison with Sos2, replicated across cell-based and in vivo readouts\",\n      \"pmids\": [\"10675333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Heterozygous Sos1 mutation dominantly enhances the phenotype of a weak EGFR allele (wa-2) in mice, producing eye defects resembling EGFR or TGF-α nulls; homozygous Sos1-null embryos die mid-gestation with cardiovascular/yolk sac defects and reduced EGF-stimulated MAP kinase activation in fibroblasts, establishing a genetic requirement for SOS1 in EGFR signaling in vivo.\",\n      \"method\": \"Genetic epistasis in mice (Sos1/EGFR double mutant); ERK activation assay in null fibroblasts\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo epistasis combined with biochemical ERK readout in knockout cells, two independent genetic approaches\",\n      \"pmids\": [\"9030684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"A frameshift insertion mutation in codon 1083 of SOS1 (insertion of cytosine between nucleotides 126,142 and 126,143) is responsible for hereditary gingival fibromatosis type 1 (HGF1); the mutation abolishes four C-terminal proline-rich SH3-binding domains, creating a truncated SOS1 chimera that retains the catalytic domain and, based on analogous transgenic mouse constructs, produces skin/tissue hypertrophy.\",\n      \"method\": \"Positional cloning, sequencing of SOS1 in affected family members, segregation analysis over four generations\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct mutation identification with segregation analysis; functional inference from analogous transgenic mouse data cited but not performed in this study\",\n      \"pmids\": [\"11868160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Truncated SOS1 carrying the hereditary gingival fibromatosis mutation localizes to the plasma membrane without growth factor stimulation, producing sustained RAS/MAPK/ERK activation, phosphorylation of Rb, and upregulation of cyclins C, D, E and E2F/DP transcription factors, driving cell cycle G1-to-S progression and increased fibroblast proliferation.\",\n      \"method\": \"Ectopic expression of wild-type and mutant SOS1 constructs; siRNA knockdown; ERK phosphorylation and cell-cycle marker immunoblotting\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ectopic expression plus siRNA with multiple biochemical and cell-cycle readouts, single lab\",\n      \"pmids\": [\"17510059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SOS1 forms a tri-complex with EPS8 and ABI1 in ovarian cancer cells; the integrity of this SOS1/EPS8/ABI1 complex is required for LPA-induced Rac activation and subsequent cell migration and peritoneal metastatic colonization; re-expression of the missing complex member in non-metastatic cells confers metastatic capability.\",\n      \"method\": \"Co-immunoprecipitation, knockdown, ectopic re-expression, Rac-GTP assay, in vivo peritoneal colonization assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus functional rescue experiments plus in vivo colonization assay, multiple orthogonal methods\",\n      \"pmids\": [\"21118970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RSK phosphorylates SOS1 on Ser1134 and Ser1161 in cultured cells; these phosphorylations create 14-3-3 docking sites, and mutating these residues disrupts 14-3-3 binding and modestly increases and extends MAP kinase activation, identifying RSK-mediated SOS1 phosphorylation as a negative feedback mechanism restraining MAPK signaling.\",\n      \"method\": \"Quantitative mass spectrometry, pharmacological RSK inhibition, mutagenesis of phosphorylation sites, 14-3-3 binding assays, ERK activation time-course\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — MS-identified phosphosites, mutagenesis confirming 14-3-3 binding, functional ERK readout; multiple orthogonal methods in one study\",\n      \"pmids\": [\"22827337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Conditional deletion of Sos1 in thymocytes reveals that SOS1 is required for pre-TCR-stimulated (DN-to-DP transition) but not TCR-stimulated developmental signals; Sos1-deficient thymocytes show reduced pre-TCR-induced proliferation, differentiation, and ERK phosphorylation, while TCR-dependent positive and negative selection remain intact.\",\n      \"method\": \"Conditional (floxed allele) knockout mice; thymocyte subset analysis; ERK phosphorylation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean conditional KO with stage-specific phenotypic readouts and biochemical ERK measurement, multiple in vivo and ex vivo approaches\",\n      \"pmids\": [\"21746917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SOS1 and Grb2 cooperatively control embryonic stem cell fate toward the primitive endoderm lineage via FGF signaling; this requires collective binding of multiple SOS1/Grb2 domains (SH3, SH2, REM, PH domains) to both protein and phospholipid ligands, providing a cooperative threshold mechanism for lineage commitment.\",\n      \"method\": \"Domain mutagenesis, protein-protein interaction assays, ES cell differentiation assays, genetic rescue experiments\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic domain mutagenesis combined with cell-fate readouts and biochemical interaction studies, multiple orthogonal methods\",\n      \"pmids\": [\"23452850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"SOS1 acts as a guanine nucleotide exchange factor for M-Ras (R-Ras3) in addition to classical RAS proteins; M-Ras GTP/GDP cycling is sensitive to SOS1 and GRF1 (GEFs) and to p120 RasGAP, demonstrating that SOS1 GEF activity extends to the M-Ras subfamily.\",\n      \"method\": \"GDP/GTP exchange assay, yeast two-hybrid, co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro GEF assay demonstrating SOS1 acts on M-Ras, single lab but direct biochemical measurement\",\n      \"pmids\": [\"10446149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"SOS1 directly binds the SH3 domain of PLC-γ1 through its C-terminal proline-rich domain; this interaction is detected both in vitro (GST pulldown) and in cells (co-immunoprecipitation); overexpression of PLC-γ1 or its SH2-SH2-SH3 domain elevates p21Ras and ERK activity, and a PLC-γ1 mutant lacking the SH3 domain cannot activate RAS, linking PLC-γ1 SH3 binding to SOS1-mediated RAS activation.\",\n      \"method\": \"GST pulldown, co-immunoprecipitation, transient expression with RAS-GTP and ERK activity assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — GST pulldown plus co-IP plus functional GEF readout, single lab, multiple methods\",\n      \"pmids\": [\"10913276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SOS1 silencing inhibits EGF-induced NFκB activation in cancer cells, and SOS1 overexpression increases NFκB activation; importantly, the guanine nucleotide exchange activity of SOS1 is NOT required for NFκB activation, indicating SOS1 has a GEF-independent scaffolding role in the EGFR–NFκB pathway.\",\n      \"method\": \"RNAi knockdown, SOS1 overexpression, NFκB reporter assays, GEF-dead mutant analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown plus OE with GEF-dead mutant control, single lab, multiple cell line confirmation\",\n      \"pmids\": [\"25071181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SOS1 is required for sustained but not transient TCR-mediated ERK activation in primary human T cells; RasGRP1 mediates transient ERK activation while both SOS1 and RasGRP1 are required for sustained ERK signaling and T-cell activation.\",\n      \"method\": \"RNAi-mediated knockdown of SOS1, SOS2, and RasGRP1 in primary human T cells; ERK phosphorylation kinetics under transient vs. sustained TCR stimulation\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — selective siRNA knockdown with defined temporal ERK readout, single lab, clean experimental design\",\n      \"pmids\": [\"24497027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SOS1, acting through the RAS/MEK/ERK pathway, is essential for tight junction formation in human bronchial epithelial cells; global microarray analysis identifies EMP1 as a major SOS1-dependent transcriptional target, and EMP1 itself is required for tight junction assembly.\",\n      \"method\": \"RNAi screen for GEFs, SOS1-specific knockdown, microarray analysis, tight junction assembly assay\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi screen followed by targeted knockdown with pathway and transcriptional readouts, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"25394671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SOS1 localizes to macrophage podosomes; its silencing results in podosome disassembly, reduced Rac-GTP loading, and impaired matrix degradation, 3D migration, transmigration through endothelial monolayers, and invasion into tumor spheroids. Abl and Src kinases (Hck, Fgr) phosphorylate SOS1 to mediate Abl/SOS1 interaction and podosome-associated Rac GEF activity.\",\n      \"method\": \"siRNA knockdown, co-immunoprecipitation, Rac-GTP pull-down assay, Matrigel invasion assay, live cell imaging of podosome markers\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — targeted siRNA knockdown with multiple functional readouts and biochemical Rac-GTP assay, single lab\",\n      \"pmids\": [\"26447228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Sos1-specific knockout in primary mouse embryonic fibroblasts causes impaired proliferation and migration, altered cytoskeletal organization, accumulation of autophagosomes containing degraded mitochondria (mitophagy), and elevated intracellular reactive oxygen species and mitochondrial superoxide; antioxidant treatment restores proliferation and morphology, establishing a mechanistic link between SOS1 and control of mitochondrial oxidative stress.\",\n      \"method\": \"Conditional 4-OHT-inducible Sos1-null MEFs; electron microscopy; mitophagy/autophagosome markers; ROS and mitochondrial superoxide fluorescent labeling; antioxidant rescue\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean conditional KO with multiple orthogonal readouts (EM, ROS assays, antioxidant rescue), mechanistic link established within single study\",\n      \"pmids\": [\"27157612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOS1 is tyrosine phosphorylated on Y1196 by ABL; this phosphorylation controls SOS1 inter-molecular interactions, is required for RAC nucleotide exchange in vitro, and is needed for PDGF-induced RAC activation and actin remodeling/cell migration. In BCR-ABL leukemic cells, Y1196 phosphorylation by BCR-ABL drives SOS1-dependent RAC activation, cell proliferation, and transformation; genetic Sos1 removal delays BCR-ABL leukemogenesis in vivo.\",\n      \"method\": \"In vitro RAC-GEF assay with phospho-Y1196 SOS1; co-immunoprecipitation; mutagenesis; Sos1 conditional knockout in bone marrow; xenograft leukemogenesis model\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro GEF reconstitution with phosphomimetic mutants, in vivo leukemogenesis model, multiple orthogonal methods\",\n      \"pmids\": [\"28819285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Two distinct RAS exchange factors, RasGRP1 and SOS1, act downstream of EGFR but in functional opposition: SOS1 drives proliferative EGFR-Ras signals, while RasGRP1 creates a negative feedback loop that limits EGFR-SOS1-RAS signals; genetic Rasgrp1 depletion in KRas-mutant or Apc-mutant mice exacerbates Ras-ERK signaling, confirming the epistatic relationship.\",\n      \"method\": \"Genetic mouse models (Rasgrp1 depletion combined with KRas or Apc mutations), ERK signaling assays, cell proliferation measurements\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in multiple mouse models combined with biochemical ERK readouts, independently confirmed in two genetic backgrounds\",\n      \"pmids\": [\"26005835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The vacuolar H+-ATPase E subunit (V-ATPase E) binds the Dbl-homology (DH) domain of SOS1, co-immunoprecipitates with SOS1 physiologically, and co-localizes with SOS1 and Rac1 in early endosomes; overexpression of V-ATPase E enhances SOS1-mediated RAC1 guanine nucleotide exchange activity and downstream JNK kinase activity, implicating V-ATPase E as a positive regulator of the SOS1-Rac1 pathway at endosomes.\",\n      \"method\": \"GST-affinity chromatography protein purification, peptide sequencing, yeast two-hybrid, co-immunoprecipitation, subcellular fractionation, in vitro Rac1-GEF assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple binding methods plus in vitro GEF activity readout, single lab\",\n      \"pmids\": [\"11560919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SOS1 mutations found in lung adenocarcinoma function as oncogenic gain-of-function: ectopic expression induces anchorage-independent growth and tumor formation in vivo; these effects require both the RAS-GEF and putative RAC-GEF activities of SOS1, and mutant SOS1-expressing cancer cells are sensitive to MEK inhibition.\",\n      \"method\": \"Ectopic expression of lung adenocarcinoma-derived SOS1 mutants; anchorage-independent growth assay; mouse xenograft tumor formation; domain mutagenesis; transcriptional profiling; MEK inhibitor sensitivity assay\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ectopic expression plus mutagenesis plus in vivo xenograft, multiple orthogonal methods demonstrating gain-of-function mechanism\",\n      \"pmids\": [\"30635434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Crystal structures of KRAS-SOS1, SOS1, and SOS2 were solved; BI-3406 binds to the catalytic domain of SOS1, preventing SOS1–KRAS interaction; this blocks GTP loading of RAS, reduces RAS-GTP levels, limits cancer cell proliferation, and attenuates feedback reactivation of MEK inhibitors, validating the SOS1 catalytic domain as a druggable interface.\",\n      \"method\": \"Crystal structure determination, biochemical SOS1–KRAS interaction assay, cellular RAS-GTP loading assay, proliferation assays, in vivo xenograft experiments\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures combined with biochemical and cellular mechanistic validation, multiple orthogonal methods\",\n      \"pmids\": [\"32816843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structures of KRAS-SOS1 and SOS1 alone were determined; small-molecule inhibitors (e.g., BAY-293, IC50 21 nM) bind the SOS1 catalytic domain at the KRAS–SOS1 interface, disrupting complex formation, blocking KRAS GTP reloading, and exerting antiproliferative activity in KRAS-driven cells.\",\n      \"method\": \"X-ray crystallography, biophysical interaction assays (SPR/ITC), cellular RAS-GTP assay, antiproliferation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures plus biophysical validation plus cellular mechanistic assays, multiple orthogonal methods\",\n      \"pmids\": [\"30683722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The crystal structure of a 14-3-3ζ dimer bound to a 13-mer SOS1 phosphopeptide motif was determined at high resolution, demonstrating that 14-3-3 proteins directly bind SOS1 at a defined PPI interface to modulate SOS1 activity in the RAS–MAPK pathway.\",\n      \"method\": \"X-ray crystallography, biochemical PPI assays\",\n      \"journal\": \"Journal of structural biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with biochemical validation, single lab, functional consequence inferred from structure rather than activity assay\",\n      \"pmids\": [\"29408703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SUMOylation of Grb2 at K56 by SUMO1 increases formation of the Grb2–SOS1 complex, leading to enhanced RAS/MEK/MAPK activation; the Grb2-K56R mutant, which cannot be SUMOylated, fails to rescue ERK activity or cell transformation when re-expressed in Grb2-knockdown cells.\",\n      \"method\": \"In vivo and in vitro SUMOylation assay, co-immunoprecipitation, ERK activation assay, cell transformation and migration assays, xenograft model\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — SUMOylation assay combined with mutagenesis rescue and co-IP, single lab, multiple functional readouts; finding concerns Grb2 modification with SOS1 as the downstream partner\",\n      \"pmids\": [\"24775912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SOS1 mediates JAK-dependent LFA-1 activation in human T lymphocytes in response to CXCL12; SOS1 downregulation impairs rapid LFA-1-mediated adhesion, underflow arrest on ICAM-1, LFA-1 affinity triggering, and CXCL12-induced RhoA and Rac1 activation, indicating a SOS1 specificity shift to Rho-GEF activity in chemokine signaling context.\",\n      \"method\": \"siRNA knockdown of SOS1 in primary human T lymphocytes; LFA-1 adhesion assays; Rac1/RhoA-GTP pull-down; phosphotyrosine analysis; JAK inhibitor experiments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — targeted siRNA with multiple functional and biochemical readouts, single lab\",\n      \"pmids\": [\"27986909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Tks5/FISH interacts with SOS1 through synergistic binding of its tandem SH3A and SH3B domains to the proline-rich domain of SOS1; a splice-variant-specific basic insertion between SH3A and SH3B in the long Tks5 isoform reduces SOS1 binding affinity ~10-fold and alters recognition of SOS1 binding motifs, establishing isoform-selective SOS1 interaction.\",\n      \"method\": \"Peptide arrays, GST pulldown, isothermal titration calorimetry, analytical ultracentrifugation, co-localization in cells\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biophysical methods (ITC, AUC) plus cell co-localization, single lab; quantitative binding data supports mechanistic conclusions\",\n      \"pmids\": [\"19464300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Phosphorylation of Y1196 on SOS1 by ABL promotes SOS1 RAC-GEF activity in vitro; the non-phosphorylatable Y1196F mutant fails to support RAC nucleotide exchange, directly linking this specific phosphorylation event to the switch in SOS1 substrate specificity from RAS-GEF to RAC-GEF.\",\n      \"method\": \"In vitro RAC nucleotide exchange assay with phosphomimetic/phospho-dead SOS1 mutants, co-IP for ABL-SOS1 interaction\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro GEF reconstitution with mutagenesis directly demonstrating mechanism, supported by in vivo co-IP and mouse leukemia model\",\n      \"pmids\": [\"28819285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RUNX1 transcriptionally activates SOS1 expression by binding to a RUNX1-binding DNA sequence in the SOS1 promoter; RUNX1 knockdown reduces SOS1 expression and dephosphorylates ErbB2/HER2, suppressing gastric cancer cell proliferation.\",\n      \"method\": \"Promoter-binding assay (ChIP-like), RUNX1 knockdown, SOS1 mRNA/protein measurement, ErbB2 phosphorylation assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, RUNX1-SOS1 promoter interaction assay without full ChIP validation from abstract; knockdown data supporting regulatory link\",\n      \"pmids\": [\"29686309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PPDPF binds GTP and transfers GTP to SOS1, enhancing SOS1 GEF activity; mutations at the PPDPF GTP-binding sites or at SOS1 residues mediating SOS1–PPDPF interaction impair SOS1 GEF activity and the tumor-promoting effects of PPDPF, defining a PPDPF–SOS1 axis for KRAS activation in pancreatic cancer.\",\n      \"method\": \"GTP-binding/transfer assay, co-immunoprecipitation, mutagenesis of interaction sites, in vitro GEF activity assay, genetic mouse PDAC model\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — GTP transfer assay plus mutagenesis plus in vitro GEF activity plus mouse model, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"36453576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"High-affinity Grb2–SOS1 interaction involves nSH3 binding to the PVPPPVPPRRRP motif and cSH3 binding to the PKLPPKTYKREH motif of the SOS1 proline-rich domain; NMR data and replica-exchange simulations define the most probable Grb2–SOS1 binding mode as simultaneous engagement of both SH3 domains at distinct SOS1 sites.\",\n      \"method\": \"NMR spectroscopy with selective methyl labeling, peptide binding assays, replica-exchange molecular dynamics simulations\",\n      \"journal\": \"Journal of the American Chemical Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural characterization of binding mode, single lab, functional validation limited to binding affinity measurements\",\n      \"pmids\": [\"31970984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GRB2 displays intramolecular allostery: phosphotyrosine-peptide binding to the SH2 domain potentiates SH3 domain interactions with SOS1 (allosteric mechanism), and the SH2 domain blocks cSH3 to enable sequential nSH3-then-cSH3 binding to SOS1 (avidity-based mechanism), providing mechanistic insight into how RTK activation promotes GRB2–SOS1 complex formation.\",\n      \"method\": \"Biochemical binding assays, NMR, fluorescence polarization with phosphotyrosine peptides and SOS1 fragments\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biophysical methods characterizing allosteric mechanism, single lab\",\n      \"pmids\": [\"34232285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Absence of both Sos1 and Sos2 in peripheral CD4+ T cells increases AKT phosphorylation upon TCR and IL-2 stimulation, likely due to increased PI3K recruitment to Grb2; this elevated PI3K/AKT activity causes downregulation of surface CD62L and impaired T-cell migration.\",\n      \"method\": \"Conditional double-knockout mice, phospho-AKT immunoblotting, PI3K–Grb2 co-immunoprecipitation, CD62L surface staining, T-cell migration assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean conditional DKO with biochemical co-IP evidence for mechanism, single lab\",\n      \"pmids\": [\"25973715\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SOS1 is a dual guanine nucleotide exchange factor (GEF) that activates both RAS (via its CDC25 catalytic domain) and RAC (via its DH domain, triggered by ABL-mediated tyrosine phosphorylation at Y1196); it is recruited to activated receptor tyrosine kinases through Grb2 SH3–proline-rich domain interactions, and its activity is negatively regulated by MAP kinase- and RSK-mediated phosphorylation of C-terminal serines that create 14-3-3 docking sites and reduce Grb2 affinity; loss-of-function studies in mice and cells demonstrate essential roles for SOS1 in sustained EGFR-RAS-ERK signaling, early T-cell development, tight junction assembly, macrophage podosome formation, and mitochondrial redox homeostasis, while gain-of-function Noonan syndrome mutations destabilize autoinhibition to produce constitutive RAS-ERK hyperactivation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SOS1 is a dual guanine nucleotide exchange factor that couples activated receptor tyrosine kinases to RAS- and RAC-family GTPases, governing proliferative signaling, cytoskeletal remodeling, and developmental cell-fate decisions [#0, #3, #4]. It is recruited to activated receptors through Grb2, which simultaneously engages distinct proline-rich motifs of the SOS1 C-terminal domain via its nSH3 and cSH3 domains; phosphotyrosine binding to the Grb2 SH2 domain allosterically potentiates this interaction, providing a switch that links RTK activation to complex assembly [#2, #32, #33]. Through its catalytic CDC25/REM module SOS1 loads GTP onto RAS proteins (including M-Ras) to drive ERK activation, and genetic ablation shows it is specifically required for sustained, but not transient, RAS-ERK signaling downstream of EGFR and the TCR, with RasGRP1 supplying the opposing transient and feedback-limiting arm [#4, #5, #12, #15, #20]. A parallel RAC-GEF activity is unmasked by ABL-mediated tyrosine phosphorylation at Y1196, switching substrate specificity toward RAC and driving actin remodeling, podosome formation, and migration, and contributing to BCR-ABL leukemogenesis [#3, #17, #29]. SOS1 activity is negatively regulated by MAP kinase- and RSK-mediated phosphorylation of C-terminal serines, which reduces Grb2 affinity and creates 14-3-3 docking sites, constituting a negative feedback loop on the pathway [#1, #9, #25]. SOS1 also supports tight junction assembly, early T-cell development, and mitochondrial redox homeostasis, and acts as a GEF-independent scaffold in EGFR-NF\\u03baB signaling [#10, #14, #16, #18]. Gain-of-function mutations that destabilize autoinhibition cause Noonan syndrome, a truncating mutation removing the C-terminal proline-rich domains causes hereditary gingival fibromatosis, and the catalytic SOS1-KRAS interface defined by crystal structures is a validated drug target [#0, #6, #7, #23, #24].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established how SOS1 is recruited to activated receptors, answering whether it engages receptors directly or via an adaptor.\",\n      \"evidence\": \"Co-immunoprecipitation and SH2/SH3 domain-binding assays in M-CSF-stimulated myeloid cells\",\n      \"pmids\": [\"7520523\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Did not resolve the precise SH3 motifs or stoichiometry of Grb2-SOS1 binding\", \"Receptor specificity beyond Fms not addressed\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined a negative-regulatory mechanism on SOS1 by mapping MAP kinase phosphosites in the proline-rich domain and linking them to Grb2 affinity.\",\n      \"evidence\": \"Site-directed mutagenesis with in vitro phosphorylation and Grb2 binding affinity measurements\",\n      \"pmids\": [\"8816480\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Did not establish in vivo kinetics of feedback\", \"Cellular consequence for ERK output not measured directly\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrated an in vivo genetic requirement for SOS1 in EGFR signaling, moving beyond biochemical association to organismal epistasis.\",\n      \"evidence\": \"Sos1/EGFR double-mutant mice and ERK assays in null fibroblasts\",\n      \"pmids\": [\"9030684\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Mechanistic basis of embryonic lethality not dissected\", \"Did not distinguish transient vs sustained signaling roles\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Extended SOS1 substrate scope by showing GEF activity toward M-Ras in addition to classical RAS.\",\n      \"evidence\": \"In vitro GDP/GTP exchange assay, yeast two-hybrid, co-IP\",\n      \"pmids\": [\"10446149\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Physiological relevance of M-Ras GEF activity unclear\", \"Single-lab biochemistry\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showed SOS1 specifically supports sustained rather than transient RAS-ERK signaling, distinguishing it from Sos2.\",\n      \"evidence\": \"Sos1 knockout mice and ERK time-course in null cells with transformation assays\",\n      \"pmids\": [\"10675333\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Molecular basis of the sustained-vs-transient distinction not defined\", \"Placental phenotype mechanism unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified V-ATPase E as a positive regulator of SOS1 RAC-GEF activity at endosomes, implicating subcellular localization in pathway control.\",\n      \"evidence\": \"Affinity purification, yeast two-hybrid, co-IP, fractionation, in vitro Rac1-GEF assay\",\n      \"pmids\": [\"11560919\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"In vivo significance of endosomal SOS1-Rac1 not established\", \"Single lab\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Revealed that SOS1 is a RAC-GEF activated by ABL tyrosine phosphorylation, defining a second signaling output for actin remodeling.\",\n      \"evidence\": \"In vitro RAC-GEF assay, co-IP, pharmacological/genetic ABL inhibition\",\n      \"pmids\": [\"15039778\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Specific phosphosite not yet mapped\", \"Coupling between RAS and RAC arms not resolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established SOS1 as a Noonan syndrome disease gene with a gain-of-function mechanism via disrupted autoinhibition.\",\n      \"evidence\": \"Genetic mapping in patients and ectopic expression of mutants with RAS/ERK readouts\",\n      \"pmids\": [\"17143285\", \"17143282\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Structural detail of autoinhibition release not resolved here\", \"Tissue-specific consequences not addressed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Linked a SOS1 C-terminal truncating mutation to hereditary gingival fibromatosis, implicating loss of proline-rich regulatory domains in disease.\",\n      \"evidence\": \"Positional cloning and segregation analysis across four generations\",\n      \"pmids\": [\"11868160\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Functional consequence inferred from analogous transgenic data, not tested here\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Provided the mechanism by which the HGF1 truncated SOS1 drives proliferation, showing constitutive membrane localization and cell-cycle entry.\",\n      \"evidence\": \"Ectopic expression, siRNA, ERK and cell-cycle marker immunoblotting\",\n      \"pmids\": [\"17510059\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Membrane-targeting mechanism of the truncated protein not defined\", \"Single-lab cell-based study\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined a SOS1/EPS8/ABI1 tri-complex required for Rac-driven migration and metastasis, placing SOS1 in a cytoskeletal effector module.\",\n      \"evidence\": \"Reciprocal co-IP, knockdown, rescue, Rac-GTP and in vivo peritoneal colonization assays\",\n      \"pmids\": [\"21118970\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Assembly hierarchy of the complex not fully resolved\", \"Upstream activating signal incompletely defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed stage-specific requirement for SOS1 in pre-TCR but not TCR signaling during T-cell development.\",\n      \"evidence\": \"Conditional knockout mice with thymocyte subset and ERK analysis\",\n      \"pmids\": [\"21746917\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Molecular basis of pre-TCR vs TCR selectivity unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified RSK as a kinase generating 14-3-3 docking sites on SOS1, defining a negative feedback loop restraining MAPK signaling.\",\n      \"evidence\": \"Quantitative MS, RSK inhibition, mutagenesis, 14-3-3 binding and ERK time-course\",\n      \"pmids\": [\"22827337\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Magnitude of feedback in vivo modest\", \"Interplay with MAP kinase phosphosites not integrated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated cooperative multivalent SOS1/Grb2 engagement as a threshold mechanism for FGF-driven lineage commitment.\",\n      \"evidence\": \"Domain mutagenesis, interaction assays, ES cell differentiation and rescue\",\n      \"pmids\": [\"23452850\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Quantitative threshold parameters not defined\", \"Phospholipid contribution mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Expanded SOS1 roles to GEF-independent scaffolding (EGFR-NF\\u03baB), tight junction assembly via EMP1, sustained TCR ERK signaling, and Grb2-SUMOylation-dependent complex formation.\",\n      \"evidence\": \"RNAi, overexpression, GEF-dead mutants, microarray, reporter, and SUMOylation assays across multiple cell systems\",\n      \"pmids\": [\"25071181\", \"25394671\", \"24497027\", \"24775912\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Scaffolding partners in NF\\u03baB pathway not identified\", \"Direct SOS1 role vs downstream EMP1 effect not fully separated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined SOS1 opposition to RasGRP1 in EGFR-RAS signaling and revealed loss of Sos restrains PI3K/AKT in T cells.\",\n      \"evidence\": \"Genetic mouse models with KRas/Apc mutations; conditional DKO T cells with phospho-AKT and migration assays\",\n      \"pmids\": [\"26005835\", \"25973715\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Molecular basis of SOS1/RasGRP1 functional partitioning unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placed SOS1 at macrophage podosomes as a Src/ABL-regulated Rac-GEF driving matrix degradation and invasion.\",\n      \"evidence\": \"siRNA, co-IP, Rac-GTP pulldown, invasion assays, live-cell imaging\",\n      \"pmids\": [\"26447228\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Distinct contributions of Src vs ABL phosphorylation not separated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked SOS1 to mitochondrial redox homeostasis, showing its loss elevates ROS and mitophagy with antioxidant-rescuable phenotypes.\",\n      \"evidence\": \"Inducible Sos1-null MEFs, EM, ROS assays, antioxidant rescue\",\n      \"pmids\": [\"27157612\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Whether redox role is GEF-dependent not determined\", \"Mechanism connecting SOS1 to mitochondria unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Pinpointed Y1196 as the ABL phosphosite that switches SOS1 to RAC-GEF activity and drives BCR-ABL leukemogenesis.\",\n      \"evidence\": \"In vitro RAC-GEF assay with phospho-Y1196 mutants, co-IP, Sos1 conditional KO, leukemia models\",\n      \"pmids\": [\"28819285\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Structural basis of the specificity switch not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided structural detail of regulatory interfaces, including 14-3-3 binding to a SOS1 phosphopeptide, and a transcriptional regulator (RUNX1) driving SOS1 expression.\",\n      \"evidence\": \"X-ray crystallography of 14-3-3\\u03b6-SOS1 peptide; RUNX1 promoter-binding and knockdown assays\",\n      \"pmids\": [\"29408703\", \"29686309\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"RUNX1-SOS1 link is Low-confidence without full ChIP validation\", \"Functional consequence of 14-3-3 binding inferred from structure\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Validated SOS1 catalytic domain as a druggable KRAS interface and confirmed cancer-derived SOS1 mutations as oncogenic gain-of-function.\",\n      \"evidence\": \"Crystal structures of KRAS-SOS1, BAY-293 inhibitor characterization, and ectopic expression of lung adenocarcinoma mutants with xenografts\",\n      \"pmids\": [\"30683722\", \"30635434\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Allosteric vs catalytic-site inhibitor selectivity across SOS isoforms not fully resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined the high-affinity Grb2-SOS1 binding mode and a clinical-grade catalytic-site inhibitor (BI-3406) that blocks feedback reactivation.\",\n      \"evidence\": \"NMR and REMD of Grb2-SOS1; crystal structures and cellular RAS-GTP assays with BI-3406\",\n      \"pmids\": [\"31970984\", \"32816843\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"In vivo durability of inhibition not addressed in these studies\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed the allosteric/avidity logic by which GRB2 SH2 phosphotyrosine binding couples RTK activation to SOS1 engagement.\",\n      \"evidence\": \"Biochemical, NMR, and fluorescence polarization assays with phosphopeptides and SOS1 fragments\",\n      \"pmids\": [\"34232285\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Cellular dynamics of the allosteric switch not measured\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified PPDPF as a GTP-supplying cofactor that enhances SOS1 GEF activity, adding a new layer to KRAS activation in pancreatic cancer.\",\n      \"evidence\": \"GTP-binding/transfer assay, co-IP, mutagenesis, in vitro GEF assay, PDAC mouse model\",\n      \"pmids\": [\"36453576\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Generality of the PPDPF-SOS1 axis beyond pancreatic cancer unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SOS1 mechanistically controls mitochondrial redox state, and whether its non-canonical scaffolding and Rho-GEF functions are GEF-domain-independent, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"No mechanism connecting SOS1 to mitochondrial ROS established\", \"Structural basis for RAS-vs-RAC substrate switching not defined\", \"GEF-independent functions lack defined molecular partners\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [0, 4, 12, 23, 24]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 17, 21, 29]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 14, 32]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 4, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7, 17]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [21]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [8, 17, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 4, 5, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 6, 22, 23]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 15, 27, 34]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [11, 4, 5]}\n    ],\n    \"complexes\": [\n      \"Grb2-SOS1 complex\",\n      \"SOS1/EPS8/ABI1 complex\"\n    ],\n    \"partners\": [\n      \"GRB2\",\n      \"ABL1\",\n      \"EPS8\",\n      \"ABI1\",\n      \"PLCG1\",\n      \"14-3-3\",\n      \"PPDPF\",\n      \"TKS5\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}